A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo

体内 抗体 卵巢癌 体外 癌症研究 ROR1型 受体酪氨酸激酶 化学 癌症 医学 生物 受体 免疫学 内科学 生物化学 生长因子 血小板源性生长因子受体 生物技术
作者
Zhengna Yin,Yuan Mao,Ningzhi Zhang,Yiping Su,Jin Zhu,Hua Tong,Huilin Zhang
出处
期刊:Biomedicine & Pharmacotherapy [Elsevier]
卷期号:119: 109420-109420 被引量:9
标识
DOI:10.1016/j.biopha.2019.109420
摘要

Over-expression of Receptor-tyrosine-kinase-like Orphan Receptor 1 (ROR1) in cancer cells has been reported in the context of several tumors (including ovarian cancer) and is associated with poor prognosis. The aim of this study was to construct a fully chimeric anti-ROR1 IgG antibody (ROR1-IgG) and investigate its antitumor activity against ovarian cancer cells, bothin vitro and in vivo. A fully chimeric anti-ROR1 IgG antibody (ROR1-IgG) eukaryotic expression vector was constructed and ROR1-IgG antibody was expressed in CHO cells. The characteristics of ROR1-IgG were investigated by ELISA, SPR, Western blotting, FACS and fluorescence staining analyses. CCK8 and wound healing assays were performed to determine inhibition and migration capacity of ovarian cancer cells after treatment with ROR1-IgGin vitro. Further, the antitumor activity of ROR1-IgG was assessed in vivo using tumor-mice xenograft model. The results showed that ROR1-IgG could specifically bind to ROR1-positive cells (HO8910 and A2780) with a high affinity. Functional studies revealed that ROR1-IgG inhibited the malignant behavior of ROR1-positive cells (HO8910 and A2780) in a time- and dose-dependent manner. These effects were not observed in ROR1-negative lose386 cells. The tumor inhibition rates following treatment with low, medium, and high concentrations of ROR1-IgG were approximately 47.72%, 53.79%, and 60.51%, respectively. In addition, the expression of Bcl-2 was obviously reduced while that of Bax was distinctly elevated in xenografts. Collectively, our findings suggest that ROR1-IgG may be a novel therapeutic agent for patients with ROR1-positive ovarian cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liyuemao完成签到,获得积分10
刚刚
Tianju发布了新的文献求助10
刚刚
1秒前
大壮完成签到,获得积分20
1秒前
归尘发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
傅宛白完成签到,获得积分20
3秒前
深情安青应助侃侃采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
Songsong发布了新的文献求助30
5秒前
小嘿嘿完成签到,获得积分10
5秒前
6秒前
小蘑菇应助Yoisun采纳,获得10
6秒前
8秒前
金鱼发布了新的文献求助10
8秒前
8秒前
无耳兔应助张东泽采纳,获得10
8秒前
陈伟杰完成签到,获得积分10
8秒前
科研小民工应助释棱采纳,获得50
8秒前
快乐小子发布了新的文献求助10
9秒前
万有引力发布了新的文献求助10
9秒前
9秒前
义气代荷完成签到,获得积分20
10秒前
10秒前
11秒前
zy发布了新的文献求助10
11秒前
小蘑菇应助taotao采纳,获得10
11秒前
可爱的函函应助Pendragon采纳,获得10
11秒前
英俊的铭应助LFY采纳,获得10
12秒前
12秒前
科研通AI5应助faker采纳,获得10
12秒前
13秒前
黄饱饱完成签到,获得积分10
13秒前
Inevitable发布了新的文献求助10
14秒前
HuaqingLiu完成签到,获得积分10
14秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546689
求助须知:如何正确求助?哪些是违规求助? 3123769
关于积分的说明 9356697
捐赠科研通 2822394
什么是DOI,文献DOI怎么找? 1551413
邀请新用户注册赠送积分活动 723398
科研通“疑难数据库(出版商)”最低求助积分说明 713736